Research ArticleArticle
Effect of Solvents on the Time-Dependent Inhibition of CYP3A4 and the Biotransformation of AZD3839 in Human Liver Microsomes and Hepatocytes
Jenny Aasa, Yin Hu, Göran Eklund, Anders Lindgren, Pawel Baranczewski, Jonas Malmquist, Dominika Turek and Tjerk Bueters
Drug Metabolism and Disposition January 2013, 41 (1) 159-169; DOI: https://doi.org/10.1124/dmd.112.047597
Jenny Aasa
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Yin Hu
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Göran Eklund
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Anders Lindgren
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Pawel Baranczewski
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Jonas Malmquist
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Dominika Turek
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
Tjerk Bueters
Drug Metabolism & Pharmacokinetics, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (J.A., Y.H., G.E., A.L., P.B., T.B.); Medicinal Chemistry, Central Nervous System & Pain iMed Science, AstraZeneca R&D, Innovative Medicines, Södertälje, Sweden (D.T.); Global Drug Metabolism & Pharmacokinetics Screening and Profiling, AstraZeneca R&D, Södertälje, Sweden (J.M.); and MetaSafe AB, Södertälje, Sweden (G.E.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Effect of Solvents on the TDI of CYP3A4
Jenny Aasa, Yin Hu, Göran Eklund, Anders Lindgren, Pawel Baranczewski, Jonas Malmquist, Dominika Turek and Tjerk Bueters
Drug Metabolism and Disposition January 1, 2013, 41 (1) 159-169; DOI: https://doi.org/10.1124/dmd.112.047597
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement